BMJ  2005;331:864 (15 October), doi:10.1136/bmj.331.7521.864

News roundup

Women with early breast cancer to be tested for trastuzumab treatment

London Susan Mayor

All women in England with early stage breast cancer are to be tested to see if they could benefit from trastuzumab (Herceptin), and approval for use of the drug by the NHS will be fast tracked once it has been licensed. The government announced these measures last week after a campaign by women demanding prompt access to this treatment.

Health Secretary Patricia Hewitt announced that all women diagnosed with early stage breast cancer would be tested for suitability for treatment with trastuzumab. The drug is a monoclonal antibody that binds to the HER2 receptor, a cell surface protein that can be tested for and which is overexpressed in about a fifth of breast cancers. The drug is currently licensed for use only in women with advanced breast cancer who test positive for HER2, but studies reported to the American Society of Clinical Oncology in May this year . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Trastuzumab for early breast cancer raises important issues
Edward C F Wilson
BMJ 2005 331: 1023. [Extract] [Full Text]

Keep politics out of it
Fiona Godlee
BMJ 2005 331: 0. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Herceptin for early breast cancer
Edward CF Wilson
bmj.com, 17 Oct 2005 [Full text]
More imponderables
Anne J Ward
bmj.com, 31 Oct 2005 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ